<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1785">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04376944</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0261</org_study_id>
    <nct_id>NCT04376944</nct_id>
  </id_info>
  <brief_title>Barrier Measures to Limit Covid-19.Nosocomial Transmission: a Cross-sectional Evaluation</brief_title>
  <acronym>EMBELLIE</acronym>
  <official_title>Evaluating Effectiveness of Barrier Measures to Limit Nosocomial Transmission: Covid-19 Prevalence Survey Among Caregivers With Various Exposures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use lay language. The Covid-19 pandemic hit France in March 2020 and stage 3 of the epidemic&#xD;
      justified the introduction of national and unprecedented containment measures from March 17,&#xD;
      2020. The Montpellier CHU experienced peak hospitalizations of Covid-19 infections in late&#xD;
      March. The estimate of the proportion of infected people in Occitania, South of France, for&#xD;
      the 11th of May 2020 is 3.1% (95% CI: 1.9-5.9) for the Occitania region, to which Montpellier&#xD;
      belongs.&#xD;
&#xD;
      In the context of the Covid-19 epidemic, notably due to the absence of pharmacological or&#xD;
      vaccine prophylaxis, barrier measures were of crucial importance, especially for exposed&#xD;
      caregivers. These measures include an adaptation of individual behavior, the creation of a&#xD;
      so-called &quot;Covid&quot; hospital, the wearing of specific equipment in all departments, the use in&#xD;
      the rooms of Covid-19 patients of a gown, an apron, gloves, and a FFP2 type mask in the event&#xD;
      of contact and sampling, protocolized and standardized bio-cleaning measures, a&#xD;
      reorganization of the premises and the definition of specific circuits.&#xD;
&#xD;
      In view of the second wave of the epidemic, estimating the effectiveness of the barrier&#xD;
      measures is of major importance. The investigators therefore propose an evaluation of the&#xD;
      effectiveness of these measures, by comparing the serological prevalence of infection among&#xD;
      caregivers working directly in COVID units compared to caregivers working in services&#xD;
      excluding the management of Covid-19 patients.&#xD;
&#xD;
      Systematic evaluation in COVID-19 units of Sarc-Co-V2 infection will also be assessed, with&#xD;
      naso-pharyngeal swabs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of caregivers and agents with a positive serodiagnosis</measure>
    <time_frame>1 day</time_frame>
    <description>Proportion of caregivers and agents with a positive serodiagnosis in COVID units versus non-COVID units</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of caregivers and agents with a positive RT-PCR</measure>
    <time_frame>1 day</time_frame>
    <description>Proportion of caregivers and agents with a positive RT-PCR in COVID units versus non-COVID units</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Caregivers</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Exposed group</arm_group_label>
    <description>Caregivers and agents working directly in COVID units compared to those living.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>caregivers anf agents working in services excluding the management of patients screened positive for Covid-19 infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey</intervention_name>
    <description>questionnaire on their symptoms and their exposures</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Exposed group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      NC&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        carers of the UH Montpellier&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  exposed group: exposed caregivers and agents who worked in COVID units (medicine,&#xD;
             resuscitation, screening) until their date of collection. An exposed agent or&#xD;
             caregiver is defined by the entrance of rooms with a COVID-19 infection during their&#xD;
             professional activity.&#xD;
&#xD;
          -  low or unexposed group: caregivers or agents who have worked in non-COVID units in a&#xD;
             non-COVID hospital&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - refusal to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Bistoquet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alain MAKINSON, MCU-PH</last_name>
    <phone>0663075260</phone>
    <phone_ext>33</phone_ext>
    <email>a-makinson@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie Bistoquet, MD</last_name>
    <email>m-bistoquet@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uh Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Bistoquet, MB</last_name>
      <email>m-bistoquet@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>barrier measures</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

